Equities

Emyria Ltd

EMD:ASX

Emyria Ltd

Actions
Health CareHealth Care Providers
  • Price (AUD)0.032
  • Today's Change0.00 / 0.00%
  • Shares traded248.80k
  • 1 Year change-55.56%
  • Beta1.2018
Data delayed at least 20 minutes, as of Nov 14 2024 02:34 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises medication-assisted treatment programs and biopharmaceuticals, specifically methylenedioxy-methylamphetamine (MDMA) analogues and Ultra-Pure cannabidiol (CBD) capsules. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

  • Revenue in AUD (TTM)2.20m
  • Net income in AUD-11.46m
  • Incorporated2018
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Avecho Biotechnology Ltd339.30k-3.48m7.92m29.00--1.88--23.35-0.0012-0.00120.00010.00130.06934.260.7043---71.20-47.08-105.46-55.25-45.6078.67-1,026.91-156.433.48--0.0316---58.07-19.42-46.71------
Zelira Therapeutics Ltd1.02m-36.57m7.94m8.00------7.76-3.22-3.220.0902-0.39790.05240.06095.06---188.05-46.98-246.20-50.1691.73---3,587.90-1,063.820.424-6.783.35---82.72-35.59-556.18------
Patrys Ltd1.39m-3.54m9.26m15.00--2.67--6.64-0.0017-0.00170.00070.00170.2386--0.6665---60.57-52.81-68.65-56.79-----253.86-249.64----0.00---51.1110.5549.88---4.41--
Chimeric Therapeutics Ltd0.00-12.53m9.95m----3.55-----0.0136-0.01360.000.00280.00-------66.56---194.88-------------58.480.5228------51.65------
Algorae Pharmaceuticals Ltd125.20k-2.10m10.97m----3.64--87.60-0.0013-0.00130.000080.00180.0338--1.81---56.60-47.73-61.85-54.26-----1,673.77-865.45---115.690.00--197.95-30.460.5741------
Adalta Ltd1.78m-5.38m11.37m----5.28--6.37-0.0111-0.01110.00360.00340.2682--0.7681---80.88-66.85-203.94-114.23-----301.55-175.59---51.020.5712---49.47-13.04-10.93---18.22--
Emyria Ltd2.20m-11.46m13.29m----5.40--6.03-0.0342-0.03420.00610.00590.2826--71.63---146.97-92.02-224.64-116.98-7.61-29.81-520.08-395.71---30.620.4147--38.3282.13-123.26---28.39--
Invion Ltd3.74m-5.63m13.63m8.00--0.9149--3.64-0.0009-0.00090.00060.00220.217--2.65---32.63-19.46-34.28-20.50-----150.33-70.20----0.00---9.54-0.7235-248.51--171.96--
BPH Energy Ltd843.69k4.56m14.60m2.00k3.120.4674--17.310.00390.00390.00080.02570.0333--11.41--17.985.1218.585.50----539.93238.65----0.0029--177.4824.84433.96------
Tissue Repair Ltd548.09k-4.14m15.42m----0.8548--28.13-0.0684-0.06840.00910.29830.02620.001.22---19.81-24.20-20.72-25.29100.00---755.00-10,570.1414.34--0.00--4,842.86--0.8698------
Medlab Clinical Ltd14.62k-2.13m15.57m14.00------1,064.94-0.9331-0.93310.0064-0.37260.009--0.2828---130.91-63.51-963.28-84.90100.0044.13-14,575.44-671.49---4,256.68-----98.45-71.5268.57------
Alterity Therapeutics Ltd268.42k-19.12m15.96m10.00--1.14--59.46-0.0052-0.00520.000070.00260.0115--8.1326,842.00-82.18-56.58-103.97-66.91-----7,124.45-22,925.08----0.0114--1,532.7319.85-38.51---4.01--
Biotron Ltd1.65m-3.44m17.60m4.00------10.70-0.0038-0.00380.0018-0.00030.7108-------148.49-77.12-234.15-92.61-120.34-127.14-208.89-238.85--------14.948.931.61------
BTC Health Ltd16.36k1.06m17.83m1.0015.943.6116.891,089.660.00350.00350.000050.01530.004------26.09-21.2227.32-22.60----6,450.37-3,306.65----0.00--23.38-38.62110.38------
Data as of Nov 14 2024. Currency figures normalised to Emyria Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.